Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17785202
Kang S, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201-14 17785202
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FGFR3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 FGFR3 (human) inhibit treatment-induced decrease
wortmannin FGFR3 (human) inhibit treatment-induced decrease

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FGFR3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 FGFR3 (human) inhibit treatment-induced decrease
wortmannin FGFR3 (human) inhibit treatment-induced decrease

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p

T359-p - p90RSK (human)
Modsite: DTEFTSRtPKDsPGI SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): , p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [RSK3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse

S363-p - p90RSK (human)
Modsite: TSRtPKDsPGIPPsA SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): S363‑p, p90RSK iso2 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): , p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [RSK3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse

S380-p - p90RSK (human)
Modsite: HQLFRGFsFVAtGLM SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [RSK3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse

T573-p - p90RSK (human)
Modsite: AENGLLMtPCytANF SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): T573‑p, p90RSK iso2 (human): T582‑p, p90RSK (mouse): T562‑p, p90RSK iso3 (mouse): , p90RSK (rat): T573‑p, p90RSK (chicken): T590‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [RSK3 (human)]
Cellular systems studied:  cell lines
Species studied:  mouse

S386-p - RSK2 (human)
Modsite: HQLFRGFsFVAItsD SwissProt Entrez-Gene
Orthologous residues
RSK2 (human): S386‑p, RSK2 (mouse): S386‑p, RSK2 (rat): S386‑p, RSK2 (cow): S386‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  myeloproliferative disorder, multiple myeloma
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FGFR3 (human)], CCLP1 (hepatic), KMS-11 (B lymphocyte), KMS-11 (B lymphocyte) [FGFR3 (mouse)], NCI-H929 (B lymphocyte), OPM-1 (B lymphocyte), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Phosphorylation of RSK2 Y29 and S386was induced in T(14:4) posative lines (KMS-11, OPM-1, LP1, H929), but not in t(14:4) lines(RPMI8226, ANBL6, U266) myeloma cell lines.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3_withdrawal, IL-3 FGFR3 (human) increase
U0126 FGFR3 (human) inhibit treatment-induced decrease
wortmannin FGFR3 (human) inhibit treatment-induced decrease
Boc-D-FMK RSK2 (human) inhibit treatment-induced decrease RSK inhibitor fmk-BODIPY, inhibits cytokine -independent proliferation of Ba/F3 cells.
Boc-D-FMK RSK2 (human) inhibit treatment-induced decrease Inhibition of RSK2 by fmk in FRFR3-expressing t(14:4)-positive Human myeloma cell lines and primary human myeloma cells induces apoptosis.

Y488-p - RSK2 (human)
Modsite: DVyDDGKyVYVVTEL SwissProt Entrez-Gene
Orthologous residues
RSK2 (human): Y488‑p, RSK2 (mouse): Y488‑p, RSK2 (rat): Y488‑p, RSK2 (cow): Y488‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FGFR3 (human)]
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE FGFR3 (human)
Comments:  FGFR3 (constitutively activated) directly phosphorylates RSK2 Y529 in an in vitro kinase assay. This facitates binding of ERK to RSK2 (co-immunoprecipitation).

Y529-p - RSK2 (human)
Modsite: TITKTVEyLHAQGVV SwissProt Entrez-Gene
Orthologous residues
RSK2 (human): Y529‑p, RSK2 (mouse): Y529‑p, RSK2 (rat): Y529‑p, RSK2 (cow): Y529‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  myeloproliferative disorder, multiple myeloma
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FGFR3 (human)], CCLP1 (hepatic), KMS-11 (B lymphocyte), KMS-11 (B lymphocyte) [FGFR3 (mouse)], NCI-H929 (B lymphocyte), OPM-1 (B lymphocyte), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Phosphorylation of RSK2 Y29 and S386was induced in T(14:4) posative lines (KMS-11, OPM-1, LP1, H929), but not in t(14:4) lines(RPMI8226, ANBL6, U266) myeloma cell lines.
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE FGFR3 (human)
Comments:  FGFR3 (constitutively activated) directly phosphorylates RSK2 Y529 in an in vitro kinase assay. This facitates binding of ERK to RSK2 (co-immunoprecipitation).
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE FGFR3 (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  apoptosis, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FGFR3 (human) Induces phosphorylation cell growth, altered co-immunoprecipitation
Comments:  FGFR3 phosphorylates RSK2 at Y529 which facilitates inactive ERK binding to RSK2.

T577-p - RSK2 (human)
Modsite: AENGLLMtPCytANF SwissProt Entrez-Gene
Orthologous residues
RSK2 (human): T577‑p, RSK2 (mouse): T577‑p, RSK2 (rat): T577‑p, RSK2 (cow): T577‑p